Payment overview · 2025
General Payments
$85.92
2 reported records · 2 companies
Healthcare provider profile · identity verified
Scott Steven Lloyd, MD
Allopathic & Osteopathic Physicians|Family Medicine · NORTH CHARLESTON, SC · NPI 1013355544
Verified facts
What the public records show
CMS Open Payments records show Scott Steven Lloyd, MD received $85.92 in general payments during 2025 across 2 reported records.
CeQur Corporation accounted for 58.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CeQur Corporation | Unresolved — no canonical attribution shown | $50.00 | 58.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $35.92 | 41.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $85.92 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $50.00 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $35.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 352 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 258 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 76 |
| Omeprazole | Omeprazole | 180 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 66 |
| Losartan Potassium | Losartan Potassium | 173 | 60 |
| Ozempic | Semaglutide | 173 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 159 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 41 |
| Mounjaro | Tirzepatide | 136 | 26 |
| Lorazepam | Lorazepam | 130 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 130 | 22 |
| Gabapentin | Gabapentin | 129 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 128 | 18 |
| Metformin Hcl Er | Metformin Hcl | 126 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 46 |
| Trazodone Hcl | Trazodone Hcl | 114 | 35 |
| Tramadol Hcl | Tramadol Hcl | 105 | 19 |
| Alprazolam | Alprazolam | 103 | 14 |
| Lisinopril | Lisinopril | 103 | 33 |
| Furosemide | Furosemide | 101 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 21 |
| Metformin Hcl | Metformin Hcl | 94 | 33 |
| Carvedilol | Carvedilol | 89 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 26 |
| Montelukast Sodium | Montelukast Sodium | 82 | 22 |
| Spironolactone | Spironolactone | 79 | 29 |
| Eliquis | Apixaban | 75 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 27 |
| Azelastine Hcl | Azelastine Hcl | 67 | 36 |
| Spiriva Respimat | Tiotropium Bromide | 66 | 11 |
| Simvastatin | Simvastatin | 62 | 20 |
| Prednisone | Prednisone | 59 | 47 |
| Valsartan | Valsartan | 59 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 15 |
| Allopurinol | Allopurinol | 52 | 15 |
| Jardiance | Empagliflozin | 52 | 18 |
| Sertraline Hcl | Sertraline Hcl | 51 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 16 |
| Pregabalin | Pregabalin | 47 | 14 |
| Synthroid | Levothyroxine Sodium | 47 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 12 |
| Potassium Chloride | Potassium Chloride | 42 | 19 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Meloxicam | Meloxicam | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 15 |
| Diazepam | Diazepam | 37 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 16 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 25 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 16 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Famotidine | Famotidine | 21 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Dronabinol | Dronabinol | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Levocarnitine | Levocarnitine | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $85.92 · 2 records | CeQur Corporation | CeQur Simplicity, Dexcom G6 Transmitter | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error